US stock · Healthcare sector · Biotechnology
Company Logo

Biohaven Pharmaceutical Holding Company Ltd.

BHVNNYSE

143.40

USD
+0.80
(+0.56%)
Market Closed
-14.45P/E
-25Forward P/E
-0.56P/E to S&P500
10.188BMarket CAP
- -Div Yield
Upcoming Earnings
8 Aug-12 Aug
Shares Short
5/13/22
4.13M
Short % of Float
6.44%
Short % of Shares Outs.
5.81%
% Held by Insiders
11.56%
% Held by Institutions
91.75%
Beta
1.20
PEG Ratio
- -
52w. high/low
151.51/79.01
Avg. Daily Volume
1.59M
Return %
Stock
S&P 500
1 year
78.58
(6.01)
3 years
133.47
39.24
5 years
497.50
63.25
Scale: |
High
Low
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
39.51
17.00
44.28
16.50
67.86
34.06
100.77
26.56
151.51
62.57
144.40
79.01
Currency: USD
- -
- -
- -
- -
- -
- -
- -
- -
- -
2015
2016
2017
2018
2019
2020
2021
TTM
Revenue per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1.08
7.87
11.05
Earnings per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
(0.77)
(4.48)
(4.57)
(6.15)
(10.91)
(13.06)
(14.41)
(11.84)
FCF per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
(0.43)
(2.08)
(3.42)
(5.14)
(7.86)
(12.74)
(14.18)
(9.74)
Dividends per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
CAPEX per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.00
0.00
0.02
0.11
0.08
0.77
0.03
0.02
Book Value per sh.
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.09
1.21
4.74
3.85
(0.15)
(6.65)
(12.59)
(8.40)
Comm.Shares outs.
- -
- -
- -
- -
- -
- -
- -
- -
- -
13
14
28
39
48
59
59
67
Avg. annual P/E ratio
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
(6.0)
(5.4)
(4.4)
(4.8)
(7.2)
(14.4)
P/E to S&P500
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
(0.3)
(0.2)
(0.2)
(0.1)
(0.2)
(0.6)
Avg. annual div. yield
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue (m)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
64
463
738
Operating margin
- -
- -
- -
- -
- -
- -
- -
- -
- -
(Infinity)%
(Infinity)%
(Infinity)%
(Infinity)%
(Infinity)%
(1,014.3)%
(152.2)%
(96.8)%
Depreciation (m)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0
- -
- -
- -
9
25
20
Net profit (m)
- -
- -
- -
- -
- -
- -
- -
- -
- -
(10)
(64)
(127)
(241)
(529)
(767)
(847)
(698)
Income tax rate
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
(0.1)%
(0.8)%
(0.2)%
(0.1)%
(1.3)%
(0.6)%
(6.7)%
Net profit margin
- -
- -
- -
- -
- -
- -
- -
- -
- -
(Infinity)%
(Infinity)%
(Infinity)%
(Infinity)%
(Infinity)%
(1,205.1)%
(183.0)%
(123.6)%
Working capital (m)
- -
- -
- -
- -
- -
- -
- -
- -
- -
2
16
127
253
262
327
342
595
Long-term debt (m)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
118
- -
267
627
634
Equity (m)
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
17
132
151
(7)
(390)
(739)
(462)
ROIC
- -
- -
- -
- -
- -
- -
- -
- -
- -
(598.5)%
(331.5)%
(89.9)%
(84.3)%
(174.6)%
(165.1)%
(146.2)%
(70.0)%
Return on capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
(497.5)%
(233.7)%
(83.4)%
(78.4)%
(140.9)%
(97.4)%
(69.3)%
(38.1)%
Return on equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
(879.5)%
(370.8)%
(96.4)%
(159.6)%
7,122.9%
196.4%
114.5%
151.0%
Plowback ratio
- -
- -
- -
- -
- -
- -
- -
- -
- -
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
Div.&Repurch./FCF
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Capital Structure
10 May · 2022 | Q1
All numbers in millions
Total liabilities
$ 1,838
Total assets
$ 1,372
Long-term debt
$ 634
Cash and equiv.
$ 169
Goodwill
$ - -
Retained earnings
$ - -
Common stock
70
Enterprise Value
$ 10,653
Working Capital
Currency: USD, in millions
2019
2020
2021
Cash & Investments
317
355
365
Receivables
3
120
308
Inventory
- -
40
81
Other
9
(96)
(22)
Current assets
328
603
876
Acc. Payable
14
48
52
Debt due
- -
- -
- -
Other
52
228
483
Current liabilities
66
277
534
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
626.91%
- -
- -
Cash flow
11.29%
77.02%
- -
Earnings
10.41%
66.08%
- -
Dividends
- -
- -
- -
Book value
89.40%
1,289.27%
- -
Insider Trading
Type
Shares
Date
Antonijevic Irina
Award
5,070
05/11/22
Clark George C.
Exempt
2,250
05/10/22
Clark George C.
Sale
4,200
05/10/22
Clark George C.
Exempt
2,250
05/10/22
Gregory Julia P
Award
8,239
04/28/22
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
1
10
18
35
64
2021
44
93
136
190
463
2022
319
- -
- -
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
(2.94)
(3.08)
(3.32)
(3.71)
(13.06)
2021
(4.51)
(3.59)
(2.93)
(3.39)
(14.41)
2022
(1.65)
- -
- -
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Biotechnology
CEO:
Mr. Vlad Coric
Full-time employees:
928
City:
New Haven
Address:
215 Church St
IPO:
May 4, 2017
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.
Recent News
· 10 May, 2022 · The Wall Street Journal